



## Predicting 5-Aminosalicylate Nephrotoxicity in patients with IBD

-an international IBD Genetics Consortium Project

**Thank you to the sites who have recently recruited: Dr S Lewis, Plymouth; Dr J Beckly, Cornwall; Dr D Grimes, Blackburn; Dr M Parkes, Cambridge; Dr J Loehry, Salisbury; Dr Sebastian; Hull; Prof C Probert, Bristol.**

### Inclusion criteria:

Any patients with history of ulcerative colitis or Crohn's disease that have 5-aminosalicylate nephrotoxicity might be eligible based on the following criteria

**Current age over 16 years**

**Normal Creatinine or eGFR at baseline.**

**≥50% rise in serum creatinine (with corresponding fall in eGFR, anytime after introduction of 5-ASA).**

**Medical opinion implicating 5-ASA justifies drug withdrawal, even if temporary**

